Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 3Leukemia, Myeloid, Chronic-Phase 2Gastrointestinal Stromal Tumors 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Blast Crisis 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × nilotinib × Clear all
NCT02379416 2026-06-01

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

NCT07138378 2025-08-22

XS003-11

Xspray Pharma AB

Phase 1 Completed
128 enrolled
Tumor-Agnostic

Neoplasms

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Novartis

Phase 1 Completed
14 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡